Carluccio et al. highlighted the efficacy of SGLT2 inhibitors in heart failure patients, showing significant reductions in LVEDV by −10.59 mL, LVESV by −8.80 mL, and an increase in LVEF by +1.98%. The gene discussed is SLC5A2; the disease is heart failure.